Gene · 5684
PSMA3: proteasome 20S subunit alpha 3
12 sourcesgene-search-2026-11-11-0.2.0
Cite this record
ConductScience Library. PSMA3: proteasome 20S subunit alpha 3. Genes, record 5684. Release gene-search-2026-11-11-0.2.0, 11 Nov 2026. https://conductscience.org/library/genes/5684
On this page
Gene
Proteins1
Reviewed human proteins whose Swiss-Prot entry states the gene.
| UniProt entry | Protein | Length | Structures | Gene stated in |
|---|---|---|---|---|
| P25788 | Proteasome subunit alpha type-3 | 255 | 179 | Ensembl, GeneID, HGNC |
Source UniProt
Patents38
Patents whose sequence listing contains this protein's exact sequence. A patent can list a sequence without claiming it.
| Publication | Published | SEQ ID NO | Protein | Source |
|---|---|---|---|---|
| JP 2026004568 A | 2026-01-14 | 59505 | P25788 | Espacenet |
| EP 4650780 A2 | 2025-11-19 | 348 | P25788 | Espacenet |
| JP 2025517970 A | 2025-06-12 | 348 | P25788 | Espacenet |
| US 11860162 B2 | 2024-01-02 | 1532 | P25788 | Espacenet |
| US 11446398 B2 | 2022-09-20 | 67857 | P25788 | Espacenet |
| JP 2022524081 A | 2022-04-27 | 170828 | P25788 | Espacenet |
| US 11078247 B2 | 2021-08-03 | 9058 | P25788 | Espacenet |
| US 10746735 B2 | 2020-08-18 | 1532 | P25788 | Espacenet |
| WO 2020043864 A1 | 2020-03-05 | 1952 | P25788 | Espacenet |
| JP 2019054813 A | 2019-04-11 | 239940 | P25788 | Espacenet |
1 to 10 of 38
See all 38 patentsDrugs7
Drugs a ChEMBL mechanism record says act on the gene's protein, through Open Targets.
| Drug | ChEMBL ID | Mechanism | Action | Source |
|---|---|---|---|---|
| BORTEZOMIB | CHEMBL325041 | 26S proteasome inhibitor | INHIBITOR | ChEMBL |
| BORTEZOMIB D-MANNITOL | CHEMBL5315122 | 26S proteasome inhibitor | INHIBITOR | ChEMBL |
| CARFILZOMIB | CHEMBL451887 | 26S proteasome inhibitor | INHIBITOR | ChEMBL |
| IXAZOMIB | CHEMBL2141296 | 26S proteasome inhibitor | INHIBITOR | ChEMBL |
| IXAZOMIB CITRATE | CHEMBL3545432 | 26S proteasome inhibitor | INHIBITOR | ChEMBL |
| MARIZOMIB | CHEMBL371405 | 20S proteasome inhibitor | INHIBITOR | ChEMBL |
| OPROZOMIB | CHEMBL2103884 | 26S proteasome inhibitor | INHIBITOR | ChEMBL |
Trials1,241
Trials of those drugs. A trial joins the gene only through a drug that acts on it.
| Trial | Drug | Phase | Results first posted | Source |
|---|---|---|---|---|
| NCT07605416 | CARFILZOMIB | PHASE2 | ClinicalTrials.gov | |
| NCT07601100 | BORTEZOMIB | PHASE1/PHASE2 | ClinicalTrials.gov | |
| NCT07600151 | BORTEZOMIB | PHASE1/PHASE2 | ClinicalTrials.gov | |
| NCT07513129 | BORTEZOMIB | PHASE1 | ClinicalTrials.gov | |
| NCT07479979 | CARFILZOMIB | PHASE1/PHASE2 | ClinicalTrials.gov | |
| NCT07464210 | BORTEZOMIB | PHASE2 | ClinicalTrials.gov | |
| NCT07463807 | CARFILZOMIB | PHASE1/PHASE2 | ClinicalTrials.gov | |
| NCT07428369 | BORTEZOMIB | PHASE2/PHASE3 | ClinicalTrials.gov | |
| NCT07391657 | BORTEZOMIB | PHASE3 | ClinicalTrials.gov | |
| NCT07391657 | CARFILZOMIB | PHASE3 | ClinicalTrials.gov |
1 to 10 of 1,241
See all 1,241 trialsNIH grants691
NIH grants whose papers are about the gene, through NIH's grant-paper links.
| Grant | Title | PSMA3 papers | Newest fiscal year |
|---|---|---|---|
| ZIAAI000904 | Staphylococcal pathogenesis | 14 | 2025 |
| ZIAAI001220 | Pathogenesis, and Outcome of Autoinflammatory Diseases, NOMID/CAPS, DIRA, CANDLE, SAVI, NLRC4-MAS, Still's-like Diseases, and other Undifferentiated Autoinflammatory Diseases | 8 | 2025 |
| R01AG011085 | Ubiquitin‐mediated proteolysis and cell cycle control | 7 | 2025 |
| ZIAHG200372 | Genetics, Pathophysiology, and Treatment of Autoinflammatory and Autoimmune Diseases | 4 | 2025 |
| P30CA008748 | Cancer Center Support Grant | 3 | 2025 |
| P30CA015704 | Cancer Center Support Grant | 3 | 2025 |
| R01AI052474 | Vaccine Assembly from Surface Proteins of Staphylococcus aureus | 3 | 2025 |
| ZIAAI000646 | Transgenic Animal Models Of Human Immune Defects | 3 | 2025 |
| ZIAAI000647 | Genes And Gene Products As Immunoadjuvants | 3 | 2025 |
| ZICES102445 | Gene Expression and Microarrays | 3 | 2025 |
1 to 10 of 691Source NIH's project files
See all 691 nih grantsPapers1,047
Newest first. Swiss-Prot's references are curated; PubTator's text mining finds papers that name the gene, not always ones about it.
| Title | Journal | Year | PMID | Found by | Source |
|---|---|---|---|---|---|
| A multi-region transcriptomic framework reveals global and region-specific ubiquitin-proteasome system biomarkers in Alzheimer's disease. | Funct Integr Genomics | 2026 | 42809130 | PubTator, text mining | PubMed |
| An Investigation to Study Morphology, Nanomechanical Attributes, Transcriptomics, and Proteomics of Tumor Associated Macrophages Derived Extracellular Vesicles in the Tumor Microenvironment. | J Anal Oncol | 2026 | 42719843 | PubTator, text mining | PubMed |
| Identification of a Ubiquitin-Independent Degron by a Reporter Assay. | Methods Mol Biol | 2026 | 42573687 | PubTator, text mining | PubMed |
| Genetic and Molecular Mechanisms of Non-Ischemic Heart Failure with Preserved Ejection Fraction: Pathway Crosstalk, Translational Implications, and Regional Genetic Context. | Int J Mol Sci | 2026 | 42511547 | PubTator, text mining | PubMed |
| RNA selectively modulates activity of virulent amyloid PSMα3 and host-defense LL-37 via phase separation and aggregation dynamics. | Elife | 2026 | 42474037 | PubTator, text mining | PubMed |
| Elevated phagocytic capacity directs innate spinal cord repair. | Cell Rep | 2026 | 42247297 | PubTator, text mining | PubMed |
| Integrative analysis of the PSMA family identifies PSMA6 as an adverse prognostic biomarker promoting bladder cancer cell proliferation. | Int J Med Sci | 2026 | 41799753 | PubTator, text mining | PubMed |
| Antimicrobial Peptides as Cross-Seeding Modulators at the Neurodegenerative-Infectious Interface. | Research (Wash D C) | 2026 | 41743850 | PubTator, text mining | PubMed |
| Mass Spectrometry-Based Proteomic Analysis of Porcine Reproductive and Respiratory Syndrome Virus NSP9 Protein with Host Proteins. | Animals (Basel) | 2025 | 41463804 | PubTator, text mining | PubMed |
| METTL14 Regulates the Expression of Genes Related to Interferon, Interleukin and MHC Class I in Nasopharyngeal Carcinoma Cells. | Cancer Med | 2025 | 41316520 | PubTator, text mining | PubMed |
1 to 10 of 1,047
See all 1,047 papersSources 12
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ChEMBL, through Open TargetsCC BY-SA 3.0
- ClinicalTrials.govNo license stated
- EMBL-EBI's patent proteinsNo added restrictions. Attribution expected
- GenBank's patent filesNo restrictions from NCBI. Submitters may hold rights
- HGNCCC0
- NCBI GenePublic domain (US government)
- NIH's project files and grant-paper linksPublic domain
- Open TargetsCC0 1.0
- PubMedNLM's terms
- PubTator 3Public domain
- UniProtCC BY 4.0
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ChEMBL, through Open TargetsCC BY-SA 3.0, for the parts from ChEMBL. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- ClinicalTrials.govnone stated
- EMBL-EBI's patent proteinsEMBL-EBI's patent protein files from the EPO, JPO, KIPO and USPTO. EMBL-EBI: "EMBL-EBI itself places no additional restrictions on the use or redistribution of the data available via its Data Resources and Tools other than those provided by the original data owners" and "EMBL-EBI expects attribution (e.g. in publications, services or products) for the use of any of its Data Resources and Tools." Read on 11 Nov 2026 at https://www.ebi.ac.uk/about/terms-of-use
- GenBank's patent filesGenBank's patent files. NCBI: "NCBI places no restrictions on the use or distribution of the GenBank data. However, some submitters may claim patent, copyright, or other intellectual property rights in all or a portion of the data they have submitted." Read on 11 Nov 2026 at https://www.ncbi.nlm.nih.gov/genbank/about/
- HGNCCC0: https://www.genenames.org/about/license/
- NCBI GeneNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
- NIH's project files and grant-paper linksPublic domain (NIH RePORTER)
- Open TargetsCC0 1.0. Open Targets asks that users cite its latest paper: Buniello et al. 2025, Open Targets Platform: facilitating therapeutic hypotheses building in drug discovery, Nucleic Acids Research 53(D1):D1467, PMID 39657122. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- PubMedNLM's terms
- PubTator 3Public domain
- UniProtCC BY 4.0. UniProt's licence file: "All databases and documents in the UniProt FTP directory may be copied and redistributed freely, without advance permission, provided that this copyright statement is reproduced with each copy." UniProt asks that users cite its latest paper: The UniProt Consortium, UniProt: the Universal Protein Knowledgebase in 2025, Nucleic Acids Research 53:D609-D617, https://doi.org/10.1093/nar/gkae1010. Read on 9 Nov 2026 at https://www.uniprot.org/help/license
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this gene from software.
The record and each of its lists are JSON, twenty rows a page. No key.
GET https://conductscience.org/api/genes/v1/5684
GET https://conductscience.org/api/genes/v1/5684/patents?page=2